Patents by Inventor Roland Janzen

Roland Janzen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190170759
    Abstract: Chemiluminescent detection systems, kits, and microfluidics devices containing same, as well as methods of production and use thereof, are disclosed. A capture antibody is attached to a surface of a microfluidics device for capturing a sandwich complex formed of target analyte bound by sensitizer and a composition comprising a single oxygen-activatable chemiluminescent compound.
    Type: Application
    Filed: February 6, 2019
    Publication date: June 6, 2019
    Applicant: Siemens Healthcare Diagnostics Inc.
    Inventors: David J. Ledden, Roland Janzen
  • Patent number: 10203344
    Abstract: Compounds include carbamate derivatives of vitamin D including vitamin D3 and vitamin D2. The compounds are useful in methods and kits for determining the presence and/or amount of vitamin D including vitamin D analogs and metabolites thereof in a sample suspected of containing the same.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: February 12, 2019
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Zhu Teng, Roland Janzen, Martin A. Drinan
  • Patent number: 9720004
    Abstract: Methods and reagents are disclosed for conducting assays. Embodiments of the present methods and reagents are concerned with chemiluminescent reagents for determining the presence and/or amount of an analyte in a sample suspected of containing the analyte. The reagent is non-particulate and comprises a binding partner for the analyte and a chemiluminescent composition comprising an olefinic compound and a metal chelate. In embodiments of an assay, a combination is provided that comprises a sample suspected of containing the analyte, a chemiluminescent reagent as described above and a sensitizer reagent capable of generating singlet oxygen. The combination is subjected to conditions for binding of the analyte to the binding partner for the analyte. The sensitizer is activated and the amount of luminescence generated by the chemiluminescent composition is detected wherein the amount of luminescence is related to the amount of the analyte in the sample.
    Type: Grant
    Filed: April 18, 2016
    Date of Patent: August 1, 2017
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Pratap Singh, Yi Feng Zheng, Liping Geng, Roland Janzen, Carsten Schelp
  • Publication number: 20160231336
    Abstract: Methods and reagents are disclosed for conducting assays. Embodiments of the present methods and reagents are concerned with chemiluminescent reagents for determining the presence and/or amount of an analyte in a sample suspected of containing the analyte. The reagent is non-particulate and comprises a binding partner for the analyte and a chemiluminescent composition comprising an olefinic compound and a metal chelate. In embodiments of an assay, a combination is provided that comprises a sample suspected of containing the analyte, a chemiluminescent reagent as described above and a sensitizer reagent capable of generating singlet oxygen. The combination is subjected to conditions for binding of the analyte to the binding partner for the analyte. The sensitizer is activated and the amount of luminescence generated by the chemiluminescent composition is detected wherein the amount of luminescence is related to the amount of the analyte in the sample.
    Type: Application
    Filed: April 18, 2016
    Publication date: August 11, 2016
    Applicant: Siemens Healthcare Diagnostics Inc.
    Inventors: Pratap Singh, Yi Feng Zheng, Liping Geng, Roland Janzen, Carsten Schelp
  • Patent number: 9347947
    Abstract: Methods and reagents are disclosed for conducting assays. Embodiments of the present methods and reagents are concerned with chemiluminescent reagents for determining the presence and/or amount of an analyte in a sample suspected of containing the analyte. The reagent is non-particulate and comprises a binding partner for the analyte and a chemiluminescent composition comprising an olefinic compound and a metal chelate. In embodiments of an assay, a combination is provided that comprises a sample suspected of containing the analyte, a chemiluminescent reagent as described above and a sensitizer reagent capable of generating singlet oxygen. The combination is subjected to conditions for binding of the analyte to the binding partner for the analyte. The sensitizer is activated and the amount of luminescence generated by the chemiluminescent composition is detected wherein the amount of luminescence is related to the amount of the analyte in the sample.
    Type: Grant
    Filed: March 12, 2009
    Date of Patent: May 24, 2016
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Pratap Singh, Yi Feng Zheng, Liping Geng, Roland Janzen, Carsten Schelp
  • Publication number: 20160103141
    Abstract: Compounds include carbamate derivatives of vitamin D including vitamin D3 and vitamin D2. The compounds are useful in methods and kits for determining the presence and/or amount of vitamin D including vitamin D analogs and metabolites thereof in a sample suspected of containing the same.
    Type: Application
    Filed: December 16, 2015
    Publication date: April 14, 2016
    Applicant: Siemens Healthcare Diagnostics Inc.
    Inventors: Zhu Teng, Roland Janzen, Martin A. Drinan
  • Publication number: 20160025736
    Abstract: Chemiluminescent detection systems, kits and microfluidics devices containing same, as well as methods of production and use thereof, are disclosed. Immunoassay technologies are widely used in the field of medical diagnostics. One example of a commercially used immunoassay is the induced luminescence Immunoassay (LOCI) technology. The currently available LOCI?? technology involves a homogeneous assay {i.e., no wash steps involved) that has high sensitivity, and the assay uses several reagents and requires that two of these reagents (referred to as a ““sensibead” and a “chemibead”) held by other immunoassay reagents to be in dose proximity to achieve a signal.
    Type: Application
    Filed: March 13, 2014
    Publication date: January 28, 2016
    Applicant: Siemens Healthcare Diagnostics Inc.
    Inventors: David J. LEDDEN, Roland JANZEN
  • Patent number: 9244083
    Abstract: Compounds include carbamate derivatives of vitamin D including vitamin D3and vitamin D2. The compounds are useful in methods and kits for determining the presence and/or amount of vitamin D including vitamin D analogs and metabolites thereof in a sample suspected of containing the same.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: January 26, 2016
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Zhu Teng, Roland Janzen, Martin A. Drinan
  • Publication number: 20140212987
    Abstract: Methods of enhancing signal ratio between calibrators in an assay for an analyte include conducting an assay for the analyte with zero concentration of analyte in a first calibrator to determine a first signal level. The reagents employed in the assay comprise an antibody reagent comprising an antibody for the analyte wherein a hinge region of the antibody is conjugated to a moiety. The assay for the analyte is also conducted with a second concentration of analyte in a second calibrator to determine a second signal level wherein the second analyte concentration is greater than zero and wherein the reagents employed in the assay comprise the antibody reagent. A ratio of the first signal level to the second signal level is determined and evaluated.
    Type: Application
    Filed: January 30, 2013
    Publication date: July 31, 2014
    Applicant: Siemens Healthcare Diagnostics Inc.
    Inventors: Pratap Singh, Roland Janzen, Jie Li, Nina Zolotarjova
  • Publication number: 20140154700
    Abstract: Compounds include carbamate derivatives of vitamin D including vitamin D3 and vitamin D2. The compounds are useful in methods and kits for determining the presence and/or amount of vitamin D including vitamin D analogs and metabolites thereof in a sample suspected of containing the same.
    Type: Application
    Filed: November 30, 2012
    Publication date: June 5, 2014
    Inventors: Zhu Teng, Roland Janzen, Martin A. Drinan
  • Patent number: 8723134
    Abstract: A correction device for a charged particle beam device for decreasing, correcting or inverting (that is adjusting) the spherical aberration of a charged particle beam is described. The correction principle is similar to that of common multipole-Correctors. But unlike common devices of that kind this new correction device gets along entirely with plane apertures having specially shaped holes in order to supply the multipoles required for correction and is therefore predestined for miniaturization and the use in multi column devices.
    Type: Grant
    Filed: October 28, 2010
    Date of Patent: May 13, 2014
    Assignee: ICT Integrated Circuit Testing Gesellschaft für Halbleiterprüftechnik mbH
    Inventor: Roland Janzen
  • Patent number: 8252605
    Abstract: The invention relates to methods and compositions for removing a dissociated species from a fluid medium solution during and after it has detached from a solid-phase immersed in said medium, thereby allowing the concentration of free species to remain close to zero, and for improving the signal to noise ratio in assays. This is achieved by employing a substrate, such as a scavenging solid-phase, having an attached binding partner or partners (“scavenger”) for the specifically binding species and which is present during storage. This substrate may also contain regions for binding signal generating components attached to the solid-phase. This substrate binds any free species bleeding off the solid phase, increasing the reliability and sensitivity of assays. A subset of the substrates in the invention additionally forms cross-linked networks of solid-phase particles that further increase the sensitivity of assays.
    Type: Grant
    Filed: April 28, 2009
    Date of Patent: August 28, 2012
    Assignee: Siemens Healthcare Diagnostics Inc
    Inventors: Roland Janzen, Carsten Ulrich Schelp
  • Publication number: 20110147605
    Abstract: A correction device for a charged particle beam device for decreasing, correcting or inverting (that is adjusting) the spherical aberration of a charged particle beam is described. The correction principle is similar to that of common multipole-Correctors. But unlike common devices of that kind this new correction device gets along entirely with plane apertures having specially shaped holes in order to supply the multipoles required for correction and is therefore predestined for miniaturization and the use in multi column devices.
    Type: Application
    Filed: October 28, 2010
    Publication date: June 23, 2011
    Applicant: ICT Integrated Circuit Testing Gesellschaft fur Halbleiterpruftechnik mbH
    Inventor: Roland JANZEN
  • Publication number: 20100233725
    Abstract: Methods and reagents are disclosed for conducting assays. Embodiments of the present methods and reagents are concerned with chemiluminescent reagents for determining the presence and/or amount of an analyte in a sample suspected of containing the analyte. The reagent is non-particulate and comprises a binding partner for the analyte and a chemiluminescent composition comprising an olefinic compound and a metal chelate. In embodiments of an assay, a combination is provided that comprises a sample suspected of containing the analyte, a chemiluminescent reagent as described above and a sensitizer reagent capable of generating singlet oxygen. The combination is subjected to conditions for binding of the analyte to the binding partner for the analyte. The sensitizer is activated and the amount of luminescence generated by the chemiluminescent composition is detected wherein the amount of luminescence is related to the amount of the analyte in the sample.
    Type: Application
    Filed: March 12, 2009
    Publication date: September 16, 2010
    Applicant: Siemens Healthcare Diagnostics Inc., a corporation of California
    Inventors: Pratap Singh, Yi Feng Zheng, Liping Geng, Roland Janzen, Carsten Schelp
  • Publication number: 20090208987
    Abstract: The invention relates to methods and compositions for removing a dissociated species from a fluid medium solution during and after it has detached from a solid-phase immersed in said medium, thereby allowing the concentration of free species to remain close to zero, and for improving the signal to noise ratio in assays. This is achieved by employing a substrate, such as a scavenging solid-phase, having an attached binding partner or partners (“scavenger”) for the specifically binding species and which is present during storage. This substrate may also contain regions for binding signal generating components attached to the solid-phase. This substrate binds any free species bleeding off the solid phase, increasing the reliability and sensitivity of assays. A subset of the substrates in the invention additionally forms cross-linked networks of solid-phase particles that further increase the sensitivity of assays.
    Type: Application
    Filed: April 28, 2009
    Publication date: August 20, 2009
    Applicant: Siemens Healthcare Diagnostics Inc.
    Inventors: Roland Janzen, Carsten Ulrich Schelp
  • Publication number: 20050112586
    Abstract: The invention relates to methods and compositions for removing a dissociated species from a fluid medium solution during and after it has detached from a solid-phase immersed in said medium, thereby allowing the concentration of free species to remain close to zero, and for improving the signal to noise ratio in assays. This is achieved by employing a substrate, such as a scavenging solid-phase, having an attached binding partner or partners (“scavenger”) for the specifically binding species and which is present during storage. This substrate may also contain regions for binding signal generating components attached to the solid-phase. This substrate binds any free species bleeding off the solid phase, increasing the reliability and sensitivity of assays. A subset of the substrates in the invention additionally forms cross-linked networks of solid-phase particles that further increase the sensitivity of assays.
    Type: Application
    Filed: November 24, 2003
    Publication date: May 26, 2005
    Inventors: Roland Janzen, Carsten Schelp
  • Patent number: 6774372
    Abstract: An electron-optical lens arrangement with an axis that can be substantially displaced, and useful for electron lithography, includes a cylinder lens and a quadrupole field. The plane of symmetry of the quadrupole field extends in the mid-plane of the gap pertaining to the cylinder lens. The focussing level of the quadrupole is oriented in the direction of the gap. The amount of the focussing refractive power belonging to the cylinder lens is twice as high as the amount of the quadrupole. A deflection system for the charged particles is connected upstream in the level of the gap pertaining to the cylinder lens and several electrodes or pole shoes, which generate a quadrupole field are provided in the direction of the gap pertaining to the cylinder lens. The electrodes or pole shoes can be individually and, preferably, successively excited and the quadrupole field can be displaced according to the deflection of the particle beam, so that the particle beam impinges upon the area of the quadrupole field.
    Type: Grant
    Filed: January 15, 2002
    Date of Patent: August 10, 2004
    Assignee: CEOS Corrected Electron Optical Systems GmbH
    Inventors: Harald Rose, Peter Schmid, Roland Janzen